Oncotarget: Sirolimus-eluting stents — opposite in vitro effects on the clonogenic cell potential

Scienmag

The cover for issue 31 of Oncotarget features Figure 4, ‘Concentration dose-response curves of sirolimus effect [55 nM-1 nM] on the number of cells per surviving colony in U2OS cell line after 2 weeks exposure,’ by Vasuri, et al.

Four Noteworthy Driving Factors in the In-Vitro Diagnostics Market | Infiniti’s Market Research Experts Discuss the Optimal Approach

BioTech 365

LONDON–(BUSINESS WIRE)–#healthcareindustry–Advancements in technology, customers’ changing expectations, and increasing investment in the healthcare industry have influenced significant growth in the in-vitro diagnostics market.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

2020 Three Scenarios of the Future In Vitro Diagnostics Market – Business-as-Usual, Economic Austerity, Technological Breakthroughs – ResearchAndMarkets.com

BioTech 365

DUBLIN–(BUSINESS WIRE)–The “2020 Three Scenarios of the Future In Vitro Diagnostics Market: Business-as-Usual, Economic Austerity, Technological Breakthroughs” report has been added to ResearchAndMarkets.com’s offering.

Keeping tabs on Covid-19: BetterLife embraces virtual clinical trials and Novan shares positive results from in vitro antiviral technology against SARS-CoV-2

The Pharma Data

This week’s round up features a digital solution for adapting clinical trials to ease the burden on the clinical research industry and an in vitro model that mimics the human airway epithelium using a newly developed technology platform.

Antibodies from patients infected with SARS-CoV in 2003 cross-neutralized SARS-CoV-2 in vitro

Scienmag

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals Antibodies in serum samples collected from patients infected with SARS-CoV during the 2003 outbreak effectively neutralized SARS-CoV-2 infection in cultured cells, according to a new study.

Renibus Therapeutics’ COVID-19 Treatment, RBT-9, Shows Antiviral Activity Against SARS-CoV-2 In Vitro

BioTech 365

– Antiviral Activity Confirmed by Early Stage Studies Conducted through the National Institute of Allergy and Infectious Diseases Preclinical Services Program and Texas Biomedical Research Institute – Patient Enrollment for Phase 2 Trial Ongoing DALLAS, Texas, Oct. 07, 2020 (GLOBE … Continue reading → GlobeNewswire

Purdue’s Avrio Health L.P. Reports Preliminary In Vitro Test Results on Study Assessing Betadine Gargle Against COVID-19

BioTech 365

–(BUSINESS WIRE)–THIS RELEASE DISCUSSES INVESTIGATIONAL USES OF BETADINE AND IS NOT INTENDED TO CONVEY CONCLUSIONS ABOUT ITS EFFICACY OR SAFETY IN TREATING AND/OR PREVENTING COVID-19 OR ANY OTHER VIRUSES. STAMFORD, Conn.–(BUSINESS BETADINE ANTISEPTIC PRODUCTS HAVE NOT BEEN DEMONSTRATED TO BE … Continue reading → Business Wire

IVD industry must be supported in COVID-19 recovery strategy, says BIVDA

Pharma Times

Industry body says in vitro diagnostics are vital to clearing the backlog of undiagnosed conditions

Draper’s Tumor-on-a-Chip Parallels In Vivo Findings of Checkpoint Inhibitor Efficacy in Mice

BioSpace

Draper, in one of the latest lab-on-a-chip advances, has shown that its dynamic, in vitro tumor microenvironment can be used to distinguish tumor responses against two different checkpoint inhibitors in three mouse lines

StemBioSys launches CELLvo™ Human Articular Chondrocytes, low passage cells for highly relevant cartilage research

Drug Discovery Today

Freshly isolated human chondrocytes exhibit a natural, biologically relevant phenotype during in vitro expansion

IVF success rates higher at clinics that provide more outcomes data

Scienmag

18, 2020) – Success rates for in vitro fertilization are higher at clinics that voluntarily share more information than required by government regulators, according to new research by faculty at the University of Colorado School of Medicine. In a review of data reported between 2014 and 2017, CU researchers found that clinics […]. AURORA, Colo.

Tests indicate modern oral nicotine products elicit lower toxicity responses than cigs

Scienmag

Credit: Bat-science.com New research by BAT indicates that modern oral products (MOPs) showed lower toxicity responses in certain assays than traditional cigarettes.

Universal Diagnostics Presents New Promising Data on Early (Pre) Cancer Detection from Cell Free DNA at European Society for Medical Oncology (ESMO)

BioTech 365

Eurobio Scientific : 2020 HALF-YEAR RESULTS

BioTech 365

M€Strengthening of financial resources Continuation of momentum expected during second half of the year Paris, October 15, 2020 – 5:35 pm Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro … Continue reading → GlobeNewswire2020 HALF-YEAR RESULTS EBITDA reaches 20.3

SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women’s Healthcare Virtual Conference

BioTech 365

Presentations to showcase in vitro activity of ibrexafungerp against fluconazole-susceptible and -resistant Candida spp. and clinical data from VANISH-303 PHASE 3 trial evaluating ibrexafungerp as a treatment for vaginal yeast infections JERSEY CITY, N.J., 12, 2020 (GLOBE NEWSWIRE) — … Continue reading → GlobeNewswire

Qosina Partners with Resolution Medical to Offer a 3D-Printed Sterile Nasal Swab for COVID-19 Testing

BioTech 365

Developed by Resolution Medical, an in vitro diagnostic and medical device manufacturer, the innovative 3D-printed sterile swab is … Continue reading → Business WireRONKONKOMA, N.Y.–(BUSINESS –(BUSINESS WIRE)–#3D–Qosina is pleased to announce they now carry a sterile 3D-printed nasopharyngeal COVID-19 testing swab for nasal mucosa specimen collection.

Eurobio Scientific launches a first rapid diagnostic test for the detection of the SARS CoV-2 virus antigen

BioTech 365

Eurobio Scientific launches a first rapid diagnostic test for the detection of the SARS CoV-2 virus antigen Paris, September 22, 2020 –6:00 pm Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life … Continue reading → GlobeNewswire

Todos Medical Expands Existing Contract for COVID-19 PCR Testing Equipment & Supplies with Wisconsin-based Laboratory to $47.5 Million

BioTech 365

OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection … Continue reading → GlobeNewswireNEW YORK, NY, REHOVOT, Israel, and SINGAPORE, Sept. 22, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical Ltd.

New EU-funded research project ‘HCA|Organoid’

Scienmag

The project seeks to kickstart the development of an open access “Organoid Cell Atlas” By creating well-characterized in vitro […].

Eurobio Scientific announces the CE marking of its COVID EBX FluCoSyn™ PCR test

BioTech 365

Eurobio Scientific announces the CE marking of its COVID EBX FluCoSyn™ PCR test Paris, September 15, 2020 –5:45 pm Eurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), a leading French group in the field of specialty in vitro medical diagnostics, announces today … Continue reading → GlobeNewswire

Laboratory Testing of Brilacidin for COVID-19 in Combination with Remdesivir Reduces Viral Load by Nearly 100 Percent

BioTech 365

Brilacidin and Remdesivir shown to act synergistically in vitro, increasing overall inhibition against the novel coronavirus to 99.85 percent in a human lung cell line Data suggest that Brilacidin and Remdesivir, with different but complementary primary mechanisms of action, may … Continue reading → GlobeNewswire

Novan Provides Pipeline and Priority Development Programs Update

BioTech 365

– Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 – – In vitro assessments of ability of NITRICIL™ to inhibit the replication mechanisms of SARS-COV-2 … Continue reading → GlobeNewswire

Todos Medical Enters Into Partnership With Pangea for COVID-19 Testing and Contact Tracing

BioTech 365

OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early … Continue reading → GlobeNewswireNEW YORK, NY, ISRAEL, and SINGAPORE, Sept. 02, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Todos Medical Ltd.

BU researchers discover how COVID-19 may trigger fatal levels of lung inflammation

Scienmag

(Boston)– Responding to the COVID-19 pandemic caused by the novel coronavirus, SARS-CoV-2, requires models that can duplicate disease development in humans, identify potential targets and enable drug testing. Specifically, access to primary human lung in vitro model systems is a priority since a variety of respiratory epithelial cells are the proposed targets of viral entry. […].

Impact of COVID-19 on the Global Diabetes Assays Industry 2020-2030 Featuring Siemens Healthineers, Abbott Labs, Roche, Danaher and Tosoh – ResearchAndMarkets.com

BioTech 365

DUBLIN–(BUSINESS WIRE)–The “Diabetes Assays (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)” report has been added to ResearchAndMarkets.com’s offering. This market model discusses in detail the impact of COVID-19 on Diabetes Assays market for the … Continue reading → Business Wire

UPDATE: Todos Medical Announces Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC

BioTech 365

OTCQB: TOMDF), an in vitro diagnostics company focused on distributing … Continue reading → GlobeNewswire– Initial Investment of $275,000 followed by up to $10 Million commitment over 24-months REHOVOT, Israel, SINGAPORE and NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Todos Medical Ltd.

New method identifies antibody-like proteins with diagnostic and therapeutic potential for SARS-CoV-2

Scienmag

Antibody-like proteins that capture and neutralize SARS-CoV-2 Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus – 4 of which also exhibited neutralizing activity – within 4 days, according to a new study.

IVD industry must be supported in COVID-19 recovery strategy, says BIVDA

The Pharma Data

Industry body says in vitro diagnostics are vital to clearing the backlog of undiagnosed conditions. BIVDA has suggest focusing on three key areas – innovation, manufacturing and people – to support and strengthen the IVD industry in the short- and long-term future.

AZ partners with RenalytixAI in chronic disease pact

The Pharma Data

In the first stage in the partnership, the companies will use KidneyIntelX, an artificial intelligence-enabled in vitro diagnostic platform, to look at further improving outcomes for patients with chronic kidney disease (CKD) and its complications, in coordination with the Mount Sinai Health System.

SMi’s 3D Cell Culture Conference 2021 – Speakers Announced

Pharma Phorum

Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.

Shionogi launches Fetcroja in the UK for aerobic Gram-negative bacteria infections

The Pharma Data

Shionogi has announced the launch of its new antibiotic in the UK for the treatment of infections due to aerobic Gram-negative bacteria in patients over 18 with limited treatment options. . Photo by hiromitsu morimoto.

Debiopharm backs €10m funding for ‘digital sedation’ firm Oncomfort

Pharma Phorum

A company that has developed a digital treatment for pain and anxiety – Belgium-based Oncomfort – has raised €10 million in first-round financing that will be used to fund international growth.

Gilead files COVID-19 drug remdesivir with FDA

Pharma Phorum

This filing is the last part of a rolling submission with the FDA that the company began in early April and could lead to a full licence for the drug, which was the first to show significant improvements in recovery time in patients with severe disease.

Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS

The Pharma Data

Supports rapid molecular detection of acute HIV infection, which is critical in curbing further disease transmission. Food and Drug Administration (FDA) approval for the cobas® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S.

Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines

The Pharma Data

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. This is the focus of vaccines in development and convalescent plasma therapy. In 2019, Roche invested CHF 11.7

Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care

The Pharma Data

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. The SARS-CoV-2 Rapid Antigen Test is for use in point of care settings for both symptomatic and asymptomatic people.

Roche announces FDA approval of FoundationOne Liquid CDx, a comprehensive pan-tumour liquid biopsy test

The Pharma Data

The test is FDA-approved to report short variants in 311 genes including rearrangements and copy number losses in BRCA1 and BRCA2 genes. The results are delivered in an integrated report that identifies alterations matched to FDA-approved therapies.

Pharma Microbiology East Coast Conference – A Virtual Conference with Remote Access

Pharma Phorum

SMi’s 3rd Annual Pharmaceutical Microbiology Conference will no longer take place in Boston. She served as the Deputy Director (Acting) in the Office of Process and Facilities (OPF)/OPQ/CDER, responsible for new, generic, and biologic drug product quality review and facility assessment.

Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems

The Pharma Data

This test is also available in markets accepting the CE mark. This test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in patients suspected by their healthcare provider of having respiratory viral infection consistent with COVID-19. Additionally, it is available in markets accepting the CE mark. Multiplexing will increase lab efficiency and save resources in the labs. In the U.S.,

Researchers Discover Genetic Errors and Rogue Antibodies in Cases of Severe COVID-19 Infection

XTalks

The two studies were recently published online in the journal Science, both of which were led by Jean-Laurent Casanova, an infectious disease geneticist at Rockefeller University. Related: Low T Cell Counts Observed in COVID-19 Patients. Mutational Errors in COVID-19 Patients.